Characterization of Enterococcus Strains Contained in Probiotic Products

DOI Web Site Web Site PubMed 被引用文献4件 参考文献23件
  • Noguchi Norihisa
    Department of Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Nakaminami Hidemasa
    Department of Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Nakase Keisuke
    Department of Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Sasatsu Masanori
    Department of Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

この論文をさがす

抄録

Probiotics are additives containing live microbes that beneficially affect a host by improving the properties of the host intestinal microflora. Recently, advances in medical treatments have led to increased numbers of immunocompromised patients; some patients contract opportunistic infections of Enterococcus species, which are considered non-pathogenic bacteria. To evaluate the safety of probiotics containing Enterococcus strains, we isolated Enterococcus from six probiotic products and compared the pathogenic genes and antimicrobial susceptibility of the probiotic strains to those of clinical isolates. Our study showed that all Enterococcus strains contained in probiotic products were E. faecium, and no vancomycin-resistant strains were found. In addition, no pathogenic genes, such as ace, agg, gelE, cylM, cylB, cylA, cpd, cob, ccf, efaAfs, efaAfm, espfs, or espfm, were found in the probiotic strains. Pulsed-field gel electrophoresis (PFGE) analysis showed obvious genetic differences between the probiotic strains and the clinical isolates. The data suggested that the probiotic Enterococcus strains were not transmitted to hospitalized patients. Therefore, our results strongly suggest that probiotic products are unlikely agents for causing opportunistic infections.

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (23)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ